You Position: Home > Paper
Concerns about anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration treatment
( views:88, downloads:273 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF OCULAR FUNDUS DISEASES
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1005-1015.2010.01.02
- Key Word:
- 黄斑变性/药物疗法;脉络膜新生血管化/药物疗法;抗体,单克隆/治疗应用;抗体,单克隆/副作用;血管内皮生长因子类;Macular Degeneration/drug therapy;Choroidal neovascularization/drug therapy;Antibodies,monoclonal/therapeutic use;Antibodies,monoclonal/adverse effects;Vascular endothelial growth factors
Abstract： The introduction of anti-vascular endothelial growth factor (VEGF) therapy represents a landmark in the management of wet age-related macular degeneration (AMD).However,as a new therapy,several problems such as durability of the therapeutic effects,medication side effects,and medication selection have emerged.We should make appoint of improving the therapeutic effect and safety by realizing the limitation of the therapy,monitoring the clinical potential adverse reactions of anti-VEGF agents,and recommending individualized treatment.
- [1]Wong TY.Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.[J].2009,148(3).
- [2]Bakri SJ,Reid JM,Snyder MR,etc.Pharmacokinetics of intravitreal bevacizumab (Avastin).[J].2007,114(5).
- [3]Yafai Y,Eichler W,Wiedemann P,etc.Antineovascular agents in the treatment of eye diseases.[J].2006,12(21).
- [4]O'Malley MR,Wong SJ,Khan S,etc.Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.[J].2006,26(8).
- [5]Rosenfeld PJ,Ciulla TA.Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.[J].2009,20(3).
- [6]Ventura AA,Dadgostar H,Chung JY.Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.[J].2009,116(9).
- [7]Peter, van Wijngaarden,Salmaan H, Qureshi.Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.[J].2008,91(5).
- [8]Ambati BK,Ianchulev S,Yoo SH,etc.Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.[J].2003,48(3).
- [9]Chua PY,Mitrut I,Armbrecht AM.Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration.[J].2009,127(7).
- [10]Nishijima K,Zhong L,Jo N,etc.Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.[J].2007,171(1).
- [11]Oshima S,Nambu H,Kaleko M,etc.Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization.[J].2004,201(3).
- [12]Hohman TC.Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.[J].2009,29(6 Suppl.).
- [13]Egido J,Lorenzo O,Tunon J,etc.Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.[J].2009,54(3).
- [14]Grisanti S,Tatar O.The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.[J].2008,27(4).
- [15]Shaw LC,Boulton ME,Ljubimov AV,etc.Retinal and choroidal microangiopathies: therapeutic opportunities.[J].2007,74(2).
- [16]Mendrinos E,Papadopoulou DN,Mangioris G.Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.[J].2009,116(9).
- [17]Ammar DA,Kimura AE,Mandava N,etc.Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections.[J].2009,40(3).
- [18]Jost M,Noel A,Lecomte J,etc.Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.[J].2007,13(8).
- [19]Smiddy WE.Economic implications of current age-related macular degeneration treatments.[J].2009,116(3).
- [20]Lowman H,Shams N,Ferrara N,etc.Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.[J].2006,26(8).